Over the last few decades, more lives have been saved from breast cancer, thanks to early detection and increasingly personalized and innovative treatments. These advances contributed to a 44% decline in the breast cancer death rate in the U.S. between 1989 and 2024. Future progress that impacts real lives depends on breakthroughs in research, driven by clinical trials and the people who participate in them.
Yet while these research discoveries can open new doors for patients, they don’t always reach or benefit everyone who needs them.

Organizations that focus on advocacy like Susan G. Komen address this gap by serving as a vital bridge between patients, researchers and regulatory agencies. Many people think patient advocacy means working with lawmakers to make sure patient needs are reflected in current legislation. That’s an important part of Komen’s work, but it’s not the whole story.
Through the Center for Public Policy (CPP), Komen works with federal and state lawmakers and regulators at every stage of drug research and development to remove barriers and bring the most promising treatments within reach of everyone affected by breast cancer. Here’s a snapshot of how the CPP champions access to breast cancer drugs by advocating for research funding, making clinical trials more representative and inclusive, and ensuring patients’ voices are at the center of the conversation.
Driving Funding for Lifesaving Federal Research
Komen’s advocacy begins before a potential treatment even enters development. The CPP advocates for federal funding for basic science research at institutions like the National Institutes of Health (NIH) and the Department of Defense (DoD), helping build a foundational understanding of breast cancer that can inform the development of future treatments.
Today, it’s critical to sustain research funding to ensure the uninterrupted development of new breast cancer treatments. The Congressional Budget Office estimates that even a 10% reduction in NIH funding would result in fewer drugs reaching the market. The CPP advocates for federal research funding to help Komen’s research investment go even further in understanding how breast cancer develops and grows.
Supporting More Inclusive Clinical Trials
As research studies move into clinical trials, Komen’s advocacy moves along with them. The CPP works with government agencies to help ensure that clinical trial rules and guidance are developed with patients’ needs in mind.
For example, Komen has submitted comments on numerous U.S. Food and Drug Administration (FDA) draft guidances for industry, supporting clinical trial designs that enable more people in the community to participate. The CPP recently submitted comments to the Department of Health and Human Services (HHS) Office of Inspector General, advocating for a policy that would allow clinical trial sponsors to remove barriers to participation and provide financial support to participants such as direct compensation for time and reimbursement of accrued expenses.
Sharing Patient Perspectives
In addition to addressing fundamental needs for clinical trials, the CPP helps regulators understand the finer details that trial data may not fully capture. While clinical trials provide important evidence about whether a treatment is effective, patient perspectives illuminate what it means to live with breast cancer, manage side effects and weigh the risks and benefits of a new treatment.
The CPP brings these patient perspectives to agencies like the FDA through letters, meetings and partnerships with other advocacy groups. This additional insight helps regulators better understand not only whether a treatment works, but also what factors patients are willing to consider when choosing a different treatment option.
Ensuring Patient Experiences Remain at the Center of the Conversation
Formal public comment periods are just one way the CPP can bring patient perspectives into the realm of policymaking. The CPP also works with Congress to communicate with agency leaders outside of established public comment periods. Congress has the authority to monitor the work of these agencies and hold them accountable, and the CPP works alongside members of Congress to ensure patient needs remain at the center of agency decisions.
Even after a drug or treatment has been approved, the CPP urges regulators to consider real-world evidence when reviewing approved treatments, including patients’ experiences beyond clinical trials. The CPP also supports policies that help prevent drug shortages and ensure patients have continual access to the treatments they need.
Breaking Down Additional Barriers to Lifesaving Treatments
Breast cancer research can change lives, but patients only benefit when they can access the treatments that come from clinical trials. By advocating for research funding and better access to treatment, the CPP keeps patients at the heart of this progress. However, getting a drug to market is only the first of many steps toward putting lifesaving treatments into the hands of those who need them.
Even after a drug is approved, patients can face significant obstacles. Cancer treatments are often very expensive and may require costly long-term monitoring and care, and policies can create administrative barriers that block patients from the drugs they need. Stay tuned to learn more about how the CPP works as a critical part of Komen’s mission to remove barriers to lifesaving care for the breast cancer community.
Want to share how research and drug development has affected your breast cancer journey? Share your story!
Learn more about how you can help protect breast cancer patients and survivors: https://www.komen.org/how-to-help/advocacy/action-center/
